tipifarnib

Known as: (+)-6-[Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, (R)-6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, 2 (1H))-quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-,(+)- 
A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
PURPOSE Ras/Raf/MAPK kinase/ERK and rearranged in transformation (RET) kinase pathways are important in thyroid cancer. We tested… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
At present, there is no method available to predict response to farnesyltransferase inhibitors (FTIs). We analyzed gene… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Review
2008
Review
2008
Increased understanding of the cellular mechanisms associated with various malignancies has allowed researchers to develop agents… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Outcomes for older adults with acute myelogenous leukemia (AML) are poor due to both disease and host-related factors. In this… (More)
  • table 2
  • table 1
  • table 3
  • figure 1
  • table 4
Is this relevant?
2007
2007
Treatment of older patients with acute myeloid leukemia (AML) represents a significant challenge. There is little evidence that… (More)
Is this relevant?
Review
2006
Review
2006
Tipifarnib is an oral nonpeptidomimetic farnesyl transferase inhibitor developed to inhibit a variety of farnesylated targets… (More)
Is this relevant?
2006
2006
Protein farnesyltransferase inhibitors (FTIs) have shown clinical responses in hematologic malignancies, but the mechanisms are… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE This pediatric phase I trial of tipifarnib determined the maximum-tolerated dose (MTD), pharmacokinetics, and… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
PURPOSE To determine whether addition of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777; Johnson and Johnson… (More)
Is this relevant?
2004
2004
Farnesyl protein transferase inhibitors (FTIs) were originally developed to inhibit oncogenic ras, however it is now clear that… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?